A Study Regarding Tissue Response During and After Treatment for Anal Cancer

ANCABio - a Study Regarding Tumour Microenvironment and the Predictive Capability of Biopsies from Anal Cancer in Predicting Response and Outcome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05939401

Acronym

ANCABio

Enrollment

400

Registered

2023-07-11

Start date

2023-12-01

Completion date

2029-12-01

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Cancer

Keywords

Anal cancer, Tumour micro environment, Chemoradiotherapy

Brief summary

The aim of this study is to improve the understanding for the tumour biology in relation to treatment response in patients with anal cancer by examining: * The tumour microenvironment * The localisation of and cellular interactions between the tumour and immune cells * The gene and protein expression by cells present in the tumour and surrounding tissue.

Detailed description

All adult patients with anal cancer presenting within the Sahlgrenska University Hospital catchment area or treated at any time at Sahlgrenska University Hospital are eligible and will be asked to participate. The patients that are newly diagnosed or that have a suspected recurrence will be offered to enter the study with biopsies as well as blood samples during the diagnostic examination that is performed under anaesthesia. Biopsies will then be taken during follow-up exams if applicable. Biopsies will also be taken during surgery if that is scheduled and in cases where surgery is not necessary biopsies will be taken if the patient undergoes examinations under anaesthesia after treatment cessation. If it is not possible to take biopsies prior treatment blood samples will still be drawn.

Interventions

OTHERBiopsies

Biopsies and blood samples will be taken at time of diagnosis or recurrence

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Newly diagnosed or recurrent anal cancer

Exclusion criteria

* No diagnosis of anal cancer, contraindication to biopsies and blood samples

Design outcomes

Primary

Measure	Time frame	Description
Tumour micro environment	2024-2029	Evaluation of immuncell infiltrates in the tumour micro environment
ctDNA	2024-2029	circulating tumour DNA

Countries

Sweden

Contacts

Primary ContactEva Angenete PI, Professor

eva.angenete@gu.se+46760514441

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026